Curis (CRIS) News Today $1.29 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.26 -0.03 (-1.94%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Curis (NASDAQ:CRIS) Coverage Initiated at StockNews.comApril 15 at 1:37 AM | americanbankingnews.comCuris’s Strategic Advancements and Promising Outlook in IRAK4 Inhibitor Space Drive Buy RatingApril 14 at 11:40 AM | tipranks.comTruist Financial Keeps Their Buy Rating on Curis (CRIS)April 10, 2025 | markets.businessinsider.comAnalyst Forecasts For Curis, Inc. (NASDAQ:CRIS) Are Surging HigherApril 3, 2025 | finance.yahoo.comCuris to Present at Upcoming Healthcare Conference in AprilApril 2, 2025 | prnewswire.comCuris reports Q4 EPS ($1.25) vs. ($2.03) last yearApril 2, 2025 | markets.businessinsider.comCuris Stock Price, Quotes and ForecastsApril 1, 2025 | benzinga.comCuris price target lowered to $16 from $20 at H.C. WainwrightApril 1, 2025 | markets.businessinsider.comCuris, Inc. (NASDAQ:CRIS) Just Reported Full-Year Earnings And Analysts Are Lifting Their EstimatesApril 1, 2025 | finance.yahoo.comCuris, Inc. (NASDAQ:CRIS) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comCuris stock plunges to 52-week low at $1.97 amid market challengesApril 1, 2025 | investing.comCuris, Inc.: Curis Provides Fourth Quarter 2024 Business UpdateApril 1, 2025 | finanznachrichten.deCuris’s Promising Clinical Developments and Strategic Path to Accelerated Approval Boost Buy RatingApril 1, 2025 | tipranks.comCuris Inc (CRIS) Q4 2024 Earnings Call Highlights: Financial Improvements and Promising ...April 1, 2025 | gurufocus.comQ4 2024 Curis Inc Earnings Call TranscriptApril 1, 2025 | gurufocus.comCuris Inc. Reports Q4 2024 Progress and FinancialsMarch 31, 2025 | tipranks.comCuris targets accelerated approval for emavusertib in PCNSL with 12-18 month enrollment timelineMarch 31, 2025 | msn.comCuris, Inc. (CRIS) Q4 2024 Earnings Call TranscriptMarch 31, 2025 | seekingalpha.comCuris Inc (CRIS) Q4 2024 Earnings: EPS of -$1.25 Beats Estimate, Revenue Surges to $3.3 MillionMarch 31, 2025 | gurufocus.comCuris eyes accelerated approval for cancer drug emavusertibMarch 31, 2025 | investing.comCuris Provides Fourth Quarter 2024 Business UpdateMarch 31, 2025 | prnewswire.comCuris to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025March 28, 2025 | prnewswire.comCuris Inc.March 18, 2025 | wsj.comCuris Inc faces potential Nasdaq delistingMarch 1, 2025 | uk.investing.comCuris Shares Gain on Results From Leukemia-Treatment StudyJanuary 2, 2025 | marketwatch.comCuris files to sell 2.4M shares of common stock for holdersDecember 24, 2024 | markets.businessinsider.comCuris stock plunges to 52-week low, hits $3.5 amid downturnDecember 13, 2024 | investing.comPromising Clinical Trial Results and Robust Financial Projections Drive Buy Rating for EmavusertibDecember 11, 2024 | markets.businessinsider.comCuris announces additional data from TakeAim leukemia studyDecember 10, 2024 | tipranks.comCuris Announces Additional Data from TakeAim Leukemia StudyDecember 10, 2024 | prnewswire.comCuris granted FDA orphan designation for emavusertibDecember 3, 2024 | tipranks.comCuris Inc (CRIS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ...November 16, 2024 | uk.finance.yahoo.comCuris Inc. Receives Buy Rating: Strong Financials and Promising Clinical Trial Progress Drive Growth PotentialNovember 16, 2024 | markets.businessinsider.comCuris, Inc. (NASDAQ:CRIS) Q3 2024 Earnings Call TranscriptNovember 15, 2024 | msn.comCuris, Inc.: Curis Provides Third Quarter 2024 Business UpdateNovember 15, 2024 | finanznachrichten.deCuris Inc. Reports Positive Q3 2024 EarningsNovember 15, 2024 | markets.businessinsider.comCuris Provides Third Quarter 2024 Business UpdateNovember 14, 2024 | prnewswire.comExamining the Future: Curis's Earnings OutlookNovember 14, 2024 | benzinga.comCuris Inc (CRIS) Q3 2024: Everything You Need to Know Ahead of EarningsNovember 13, 2024 | gurufocus.comCuris to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024November 7, 2024 | prnewswire.comCuris price target lowered to $20 from $26 at H.C. WainwrightNovember 1, 2024 | markets.businessinsider.comCuris Inc. Gains ‘Buy’ Rating Amid Financial Stability and Promising Clinical DevelopmentsNovember 1, 2024 | markets.businessinsider.comCuris sells 2.398M shares at $4.92 in registered direct offeringOctober 29, 2024 | markets.businessinsider.comCuris Announces $12.1 Million Registered Direct and Concurrent Private PlacementOctober 29, 2024 | prnewswire.comCuris Inc (CRIS) Q2 2024 Earnings Call Highlights: Promising Clinical Progress Amid Financial ...October 9, 2024 | finance.yahoo.comBuy Rating Affirmed for Curis on Emavusertib’s Promising Clinical Data and Market PotentialSeptember 28, 2024 | markets.businessinsider.comCuris Announces the 3rd Annual Symposium on IRAK4 in CancerSeptember 23, 2024 | prnewswire.comNBC 'reaches decision on Cris Collinsworth's Sunday Night Football future'September 22, 2024 | dailymail.co.ukCuris to Participate at the Upcoming 2024 Cantor Fitzgerald Global Healthcare ConferenceSeptember 17, 2024 | prnewswire.comCuris to Present at Upcoming Healthcare Conferences in SeptemberSeptember 4, 2024 | prnewswire.com Remove Ads Get Curis News Delivered to You Automatically Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter. Email Address CRIS Media Mentions By Week CRIS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRIS News Sentiment▼0.880.80▲Average Medical News Sentiment CRIS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRIS Articles This Week▼41▲CRIS Articles Average Week Remove Ads Get Curis News Delivered to You Automatically Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Dominari News Today Bolt Biotherapeutics News Today SAB Biotherapeutics News Today Molecular Templates News Today Amgen News Today Gilead Sciences News Today Vertex Pharmaceuticals News Today Regeneron Pharmaceuticals News Today Alnylam Pharmaceuticals News Today Biogen News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRIS) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Curis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CRIS Stock Free CRIS Stock Alerts